Perspectives by the Leerink Center for Pharmacoeconomics
Perspectives by the Leerink Center for Pharmacoeconomics
Podcast Description
Welcome to Perspectives, a signature podcast series from the Leerink Center for Pharmacoeconomics. Hosted by Dr. Mel Whittington, a health economist and Head of the Center for Pharmacoeconomics, we will be hearing from individuals across the industry to better understand and appreciate the societal impact of healthcare innovations.
Podcast Insights
Content Themes
The podcast focuses on healthcare innovations, cost-effectiveness analysis, and the societal impact of health policies, with episodes including discussions on Generalized Cost Effectiveness Analysis (GCEA) and communication strategies for health impacts. Specific themes also cover the intersection of health journalism and economics.
Welcome to Perspectives, a signature podcast series from the Leerink Center for Pharmacoeconomics. Hosted by Dr. Mel Whittington, a health economist and Head of the Center for Pharmacoeconomics, we will be hearing from individuals across the industry to better understand and appreciate the societal impact of healthcare innovations.
Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with John M. O’Brien, PharmD, MPH, President and CEO of the National Pharmaceutical Council & Former Trump Drug Pricing Advisor, to tackle some big questions like if it is possible to reward innovation without busting budgets and how to get to a sustainable, innovation-friendly, patient-centered drug pricing system. Additional resources:
Subscribe to NPC’s Newsletter
https://www.npcnow.org/subscribe-updates
IRA Impact on Pharmaceutical Investment: Insights From Investor Interviews (Health Affairs Scholar)
https://academic.oup.com/healthaffairsscholar/article/3/9/qxaf156/8223954
How Time Is Accounted For When Modeling Pharmaceutical Impacts: Investment vs Assessment Perspectives (Health Affairs Scholar)
https://academic.oup.com/healthaffairsscholar/article/3/9/qxaf169/8244606
The IRA and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials (Therapeutic Innovation & Regulatory Science)
https://link.springer.com/article/10.1007/s43441-025-00774-2
Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act (Therapeutic Innovation & Regulatory Science)
https://link.springer.com/article/10.1007/s43441-024-00706-6
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications (American Journal of Managed Care)
https://www.ajmc.com/view/unintended-consequences-of-the-inflation-reduction-act-clinical-development-toward-subsequent-indications
The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs (Value in Health)
https://www.valueinhealthjournal.com/article/S1098-3015(25)02527-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301525025276%3Fshowall%3Dtrue
Follow John O’Brien on LinkedIn
https://www.linkedin.com/in/drjmob/
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.